FluoGuide A/S
BiotechnologyView the employees at
FluoGuide A/S-
Anne P. Senior Clinical Project Manager at FluoGuide
-
Copenhagen, Capital Region, Denmark
-
Top 5%
Sophie Thorsti Møller Rønnstad MSc in Business Administration and Innovation in Health Care | Market Analysis Manager at FluoGuide-
Copenhagen, Capital Region, Denmark
-
Rising Star
Morten Albrechtsen CEO at FluoGuide A/S-
Copenhagen, Capital Region, Denmark
-
Top 5%
Karina Juhl Industrial Post doc at FluoGuide A/S-
Copenhagen, Capital Region, Denmark
-
Top 5%
Michael Engsig CEO hos Nykode Therapeutics (Formerly Vaccibody)-
Copenhagen, Capital Region, Denmark
-
Top 10%
Overview
FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products is expected to have a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company has demonstrated efficacy of FG001 as well as it being well tolerated and safe in the completed proof-of-concept clinical study (phase I/IIa) in patients with high grade glioma undergoing surgery. A phase IIb trial in aggressive brain cancer is ongoing to obtain valuable information to design the phase III trial. In addition, FluoGuide currently explores FG001 lung and head & neck cancer, and a trail in in meningioma and low grade glioma is commencing. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker “FLUO”.
-